Sign in
Not yet recruitingNo phase

Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population

Key facts

Who runs it
Indizen Optical Technologies, S.L.U.
Where
Portugal, Spain, and United Kingdom3 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
180 people, planned
Started
Apr 2026
Expected to end
Oct 2028
Type of study
Observational
Treatments tested
  • myopia control lens
Record updated
5 March 2026

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Be aged between 6 to 12 completed years (6 and 12 years inclusive), irrespective of gender
  • For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old
  • Be cycloplegic autorefraction spherical component -0.50 D to -6.00D, cylinder no more than -2.00D, and with a spherical equivalent greater than or equal to -6.00D
  • Be accompanied by parents/guardians who can read and comprehend give informed consent as demonstrated by signing a record of informed consent
  • Be willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator
  • Have ocular health findings considered to be "normal"
  • Be correctable to at least 6/9.5 (20/30) or better in each eye with spectacles
  • Be willing to wear the spectacles provided by the investigators for all waking hours

Who cannot take part

  • Had previous eye surgery (including strabismus surgery)
  • Use of or need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial
  • No previous myopia management intervention or treatment
  • A known allergy to, or a history of intolerance to cyclopentolate or topical anesthetics
  • Any ocular, systemic or other condition or disease with possible associations with myopia or affecting refractive development e.g. Marfan syndrome, retinopathy of prematurity, diabetes
  • Had any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids
  • Any anatomical, skin or other condition that would impact on the wearing of spectacles
  • Had strabismus and/or amblyopia
  • Cylinder more than -2.00D
  • Anisometropia greater than 1.50D spherical equivalent
  • Current orthoptic treatment or vision training
  • Currently enrolled in another clinical trial

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 6 and 12 years old?

Where is this trial?

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The Goal of the study is to evaluate the rate of myopia progression with open ring myopia control spectacle lens designs compared to a commercial peripheral plus myopia control spectacle lens (CML) in European children with myopia. This is a prospective, randomized, bilateral wear, double masked, cross-over clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).

Read full original descriptionShow less

Group 2 - 60 participants will wear the Open Ring 1 (OR1) lens design. Group 3 - 60 participants will wear the Open Ring 2 (OR2) lens design. For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old. All groups will be required to wear spectacles for all waking hours for 12 months. After 12 months, the control group will continue wearing CML for a further 12 months; the Group 2 participants will continue wearing the OR1 lens for a further 12 months. The Group 3 participants will wear OR2 or OR3 (a modified design of OR2) based on their risk of myopia progression for a further 12 months

Treatments tested

  • myopia control lens

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07394556, who can take part
Record updated
5 March 2026